Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 7/2006

01-07-2006 | Special Article

Early satiety in cancer patients: a common and important but underrecognized symptom

Authors: Mellar P. Davis, Declan Walsh, Ruth Lagman, Tugba Yavuzsen

Published in: Supportive Care in Cancer | Issue 7/2006

Login to get access

Abstract

Introduction

The severity of anorexia correlates with the presence of early satiety. The sense of fullness limits nutritional intake. The symptom is poorly understood because most assessment questionnaires do not include early satiety.

Methods

Patients rarely volunteer early satiety. Central and peripheral mechanisms may be involved in the genesis of early satiety. These would include central sensory specific satiety, food aversions, diurnal changes in intake, gastric motility and accommodation and as gastrointestinal hormones.

Conclusions

Prokinetic medications, such as metoclopramide are used to treat early satiety. However, other medications which influence gastric accommodation such as clonidine, sumatriptan, or sildenafil, or diminish enteric afferent output such as kappa opioid receptor agonists, may favorably influence early satiety and should be subject to future research. Translational research is needed to understand the relationship of early satiety to gastric motility and accommodation.
Literature
1.
Sarhill N, Christie R (2002) Early satiety in advanced cancer: a common unrecognized symptom (letter)? Am J Hospice Palliat Care 19(5):305CrossRef
2.
Theologides A (1976) Anorexia-producing intermediary metabolites. Am J Clin Nutr 29:552–558PubMed
3.
4.
Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8(3):175–179PubMedCrossRef
5.
Armes PJ, Plant HJ, Allbright A, Silverstone T, Slevin ML (1992) A study to investigate the incidence of early satiety in patients with advanced cancer. Br J Cancer 65(3):481–484PubMed
6.
Donnelly S, Walsh D (1995) The symptoms of advanced cancer. Semin Oncol 22(2 Suppl 3):67–72PubMed
7.
Donnelly S, Walsh D, Rybicki L (1995) The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 11(1):27–32PubMed
8.
Komurcu S, Nelson KA, Walsh D, Ford RB, Rybicki LA (2002) Gastrointestinal symptoms among inpatients with advanced cancer. Am J Hospice Palliat Care 19(5):351–355CrossRef
9.
Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, LeGrand S, Abdullah O, Rybicki L (2003) Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 11(10):652–659PubMedCrossRef
10.
Nielsen SS, Theologides A, Vickers ZM (1980) Influence of food odors on food aversions and preferences in patients with cancer. Am J Clin Nutr 33(11):2253–2261PubMed
11.
Homsi J, Walsh D, Nelson KA, Gvozdjan D, Pham H, Rivera N (2001) Symptom assessment in advanced cancer: patient reports versus systematic assessment. Proc ASCO 20(Pt 1 of 2):1541
12.
Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J (2000) Re-validation and shortening of the functional assessment of anorexia/cachexia therapy (FAACT) questionnaire. Qual Life Res 9(10):1137–1146PubMedCrossRef
13.
Cella DF, Von Roenn J, Lloyd S, Browder HP (1995) The Bristol-Myers anorexia/cachexia recovery instrument (BACRI): a brief assessment of patients’ subjective response to treatment for anorexia/cachexia. Qual Life Res 4(3):221–231PubMedCrossRef
14.
Thoresen L, Fjeldstad I, Krogstad K, Kaasa S, Falmer UG (2002) Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med 16:33–42PubMedCrossRef
15.
Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ (2003) Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom index. Aliment Pharmacol Ther 18(1):141–150PubMedCrossRef
16.
Parker BA, Sturm K, MacIntosh CG, Feinle C, Horowitz M, Chapman IM (2004) Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects. Eur J Clin Nutr 58(2):212–218PubMedCrossRef
17.
Strubbe JH, Woods SC (2004) The timing of meals. Psych Rev 111(1):128–141CrossRef
18.
Graaf CD, Dejong LS, Lambers AC (1999) Palatability affects satiation but not satiety. Physiol Behav 66(4):681–688PubMedCrossRef
19.
De Graaf C, WAM Blom, PAM Smeets, Stafleu A, Hendriks HFJ (2004) Biomarkers of satiation and satiety. Am J Clin Nutr 79:946–961PubMed
20.
Erkurt E, Erkisi M, Tunali C (2000) Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. J Exp Clin Cancer Res 19(4):431–439PubMed
21.
de Castro JM (2004) The time of day of food intake influences overall intake in humans. J Nutr 134(1):104–111PubMed
22.
Strubbe JH, van Dijk G (2002) The temporal organization of ingestive behavior and its interaction with regulation of energy balance. Neurosci Biobehav Rev 26(4):485–498PubMedCrossRef
23.
Beglinger C, Degen L (2002) Role of thyrotrophin releasing hormone and corticotrophin releasing factor in stress related alterations of gastrointestinal motor function. Gut 51:45–49CrossRef
24.
Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm, Schubert M, Auer D (2003) The endogenous cannabinoid system affects energy balance via orexigenic drive and peripheral lipogenesis. J Clin Invest 112(3):423–431PubMed
25.
Powley TL, Phillips RJ (2004) Gastric satiation is volumetric, intestinal satiation is nutritive. Physiol Behav 82:69–74PubMedCrossRef
26.
Nelson KA, Walsh D (2002) Autonomic nervous system dysfunction in advanced cancer. Support Care Cancer 10:523–528PubMedCrossRef
27.
Delgado-Aros S, Chial HJ, Cremonini F, Ferber I, McKinzie S, Burton DD (2003) Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 18(5):507–514PubMedCrossRef
28.
Delgado-Aros S, Camilleri M (2005) Visceral hypersensitivity. J Clin Gastroenterol 39(4 Suppl S):S194–S203CrossRefPubMed
29.
Kraly FS (2004) Eating provides important physiological signals for satiety and drinking. Physiol Behav 82:49–52PubMedCrossRef
30.
Kim DY, Delgado-Aros S, Camilleri M, Samsom M, Murray JA, O’Connor MK (2001) Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol 96(11):3099–3105PubMedCrossRef
31.
Simonian HR, Maurer AH, Knight LC, Kantor S, Kontos D, Megalooikonomou V (2004) Simultaneous assessment of gastric accommodation and emptying: studies with liquid and solid meals. J Nucl Med 45:1155–1160PubMed
32.
Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA (2003) Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 1(4):264–272PubMedCrossRef
33.
Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssen J (2003) Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 52:1271–1277PubMedCrossRef
34.
Boeckxstaens GE, Hirsch DP, van den Elzen BD, Heisterkamp SH, Tytgat GN (2001) Impaired drinking capacity in patients with functional dyspepsia: relationship with proximal stomach function. Gastroenterol 121(5):1054–1063CrossRef
35.
Jones KL, Doran SM, Hveem K, Bartholomeusz FD, Morley JE, Sun WM (1997) Relation between postprandial satiation and antral area in normal subjects. Am J Clin Nutr 66(1):127–132PubMed
36.
Sarnelli G, Sifrim D, Janssens J, Tack J (2004) Influence of sildenafil on gastric sensorimotor function in humans. Am J Physiol Gastrointest Liver Physiol 287(5):G988–G992PubMedCrossRef
37.
Hornbuckle K, Barnett JL (2000) The diagnosis and work-up of the patient with gastroparesis. J Clin Gastroenterol 30(20):117–124PubMedCrossRef
38.
Syed AA, Rattansingh A, Furtado SD (2005) Current perspectives on the management of gastroparesis. Postgrad Med 51(1):54–60
39.
Nelson KA, Walsh TD, Sheehan FG, O’Donovan PB, Falk GW (1993) Assessment of upper gastrointestinal motility in the cancer-associated dyspepsia syndrome. J Palliat Care 9(1):27–31PubMed
40.
Shivshanker K, Bennett RW, Haynie TP (1983) Tumor-associated gastroparesis: correction with metoclopramide. Am J Surg 145(2):221–225PubMedCrossRef
41.
Wilson J, Plourde JY, Marshall D, Yoshida S, Chow W, Harsanyi Z (2002) Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. J Palliat Care 18(2):84–91PubMed
42.
Perkel MS, Hersh T, Moore C, Davidson ED (1980) Metoclopramide therapy in fifty-five patients with delayed gastric emptying. Am J Gastroenterol 74(3):231–236PubMed
43.
Edholm T, Levin F, Hellström PM, Schmidt PT (2004) Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regul Pept 121:25–30PubMedCrossRef
44.
Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand SB (2004) Appetite and cancer-associated anorexia: a review. J Clin Oncol 22(8):1510–1517PubMedCrossRef
45.
Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C (2004) Ghrelin increases energy intake in cancer patients impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89(6):2832–2836PubMedCrossRef
46.
Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H (2003) Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 9(2):774–778PubMed
47.
Janssen JA, van der Lely AJ, Lamberts SW (2004) Is there a role of ghrelin in preventing catabolism? J Endocrinol Invest 27(4):400–403PubMed
48.
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86(12):5992–5995PubMedCrossRef
49.
Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25(6):781–792PubMedCrossRef
50.
Bray GA (2000) Afferent signals regulating food intake. Proc Nutr Soc 59(3):373–384PubMed
51.
Blundell JE, Lawton CL, Cotton JR, Macdiarmid JI (1996) Control of human appetite: implications for the intake of dietary fat. Annu Rev Nutr 16:285–319PubMedCrossRef
Metadata
Title
Early satiety in cancer patients: a common and important but underrecognized symptom
Authors
Mellar P. Davis
Declan Walsh
Ruth Lagman
Tugba Yavuzsen
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 7/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0015-4

Other articles of this Issue 7/2006

Supportive Care in Cancer 7/2006 Go to the issue

Original Article

Who helps the leaders? Difficulties experienced by cancer support group leaders

Editorial

The silent symptom early satiety: a forerunner of distinct phenotypes of anorexia/cachexia syndromes

Original Article

Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study

Short Communication

Advocacy skills training for young adult cancer survivors: the Young Adult Survivors Conference at Camp Māk-a-Dream

Forthcoming Meetings

Forthcoming Meetings

Review Article

A meta-analysis of exercise interventions among people treated for cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits